Shares of IPSEN (OTCMKTS:IPSEY – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 5,001 shares were traded during trading, an increase of 119% from the previous session’s volume of 2,287 shares.The stock last traded at $46.94 and had previously closed at $48.76.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, IPSEN has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on IPSEN
IPSEN Price Performance
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Featured Articles
- Five stocks we like better than IPSEN
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
